OCT 27, 2020 8:00 AM PDT

A Super Sensitive Alzheimer's Test Powered by Nanozymes

WRITTEN BY: Tara Fernandez

Simple tasks are now uphill struggles, social situations aren’t fun, and the house keys are missing again. By the time these symptoms of Alzheimer’s disease begin to take a toll on a patient’s quality of life, the damage is done — there is already severe neurodegeneration. 

Scientists at Washington State University (WSU) have revealed a diagnostic innovation for Alzheimer’s that is 10 times more powerful than existing technologies, which could make it possible for doctors to detect the onset of the disease much earlier.

Existing diagnostic methods rely heavily on brain imaging technologies such as magnetic resonance imaging, or MRI, and CT scans. Here, physicians are looking for structural changes in the neuroanatomy, particularly shrinkage in the temporal and parietal lobes of the brain. Another (more painful) option is to take a sample of spinal fluid and analyze it for the presence of beta-amyloid biomarkers.

The team at WSU has developed a single-atom nanozyme: a synthetic enzyme that detects the presence of Alzheimer’s biomarkers with unprecedented sensitivity. These nanostructures, composed of carbon nanotubes coated with iron atoms, can detect trace amounts of beta-amyloid proteins, at levels 10 times lower than if conventional enzyme-linked immunosorbent assays (ELISA) were used. With this level of sensitivity, Alzheimer’s biomarkers could be picked up in blood samples from patients without the need for spinal taps.

“The nanozyme based on a single-atom catalyst that we created has a similar structure as a natural enzyme with remarkable enzyme-like activity and paved the way for detecting the Alzheimer’s Disease biomarker,” said Professor Dan (Annie) Du from WSU’s School of Mechanical and Materials Engineering who led the study. These novel molecules are also superior to ELISAs that use naturally-derived enzymes in that they are more cost-effective and have a much longer shelf life.

The team plans to continue the study by validating the newly-developed assay using blood samples from Alzheimer’s patients and healthy controls.

“This shows great potential for the early-stage diagnosis of Alzheimer’s Disease,” commented Du. 

Sources: Washington State University, Research.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 07, 2020
Cancer
Immune-Related Genes as Prognostic Biomarkers
AUG 07, 2020
Immune-Related Genes as Prognostic Biomarkers
Cancer is one of the most persistent and hardy diseases. Cancers often develop the ability to suppress the immune system ...
AUG 25, 2020
Cardiology
Doing More with Less: Making the Diagnosis of Heart Damage Easier for Patients
AUG 25, 2020
Doing More with Less: Making the Diagnosis of Heart Damage Easier for Patients
Cardiovascular health can be a tricky thing to diagnose. Sometimes it can be done with simple heart rate and blood press ...
SEP 03, 2020
Cardiology
Does Hypertension Make It Harder to Recognize Others Emotions?
SEP 03, 2020
Does Hypertension Make It Harder to Recognize Others Emotions?
Have you ever felt your blood pressure rise when you get angry or stressed? Well, this phenomenon is unique in that it l ...
SEP 14, 2020
Clinical & Molecular DX
Cell Line Authentication Using STR Analysis
SEP 14, 2020
Cell Line Authentication Using STR Analysis
Imagine you’re studying colon cancer using a colon cell line model. After three painstaking years of research, you ...
NOV 14, 2020
Cannabis Sciences
Half of CBD Users Test Positive for THC in Urine Tests
NOV 14, 2020
Half of CBD Users Test Positive for THC in Urine Tests
Despite the growing popularity of cannabidiol (CBD) products, there has been little research directly assessing whether ...
NOV 16, 2020
Clinical & Molecular DX
How the CRISPR-based COVID Microlab Can Intercept the Pandemic
NOV 16, 2020
How the CRISPR-based COVID Microlab Can Intercept the Pandemic
The demand for diagnostic technologies to track COVID-19 infections and control community spread of the disease has only ...
Loading Comments...